Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
about
The role of neoadjuvant therapy in the management of locally advanced renal cell carcinomaCytoreductive surgery in the era of targeted molecular therapyRapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patientsChoi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Molecular diagnosis and therapy of kidney cancer.Targeted therapies in renal cell cancer: recent developments in imagingExpression of drug targets in primary and matched metastatic renal cell carcinoma tumors.The prospects of pazopanib in advanced renal cell carcinoma.The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancerNeoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinomaPhase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.Current status of targeted therapy for advanced renal cell carcinomaNeo adjuvant treatment with targeted molecules for renal cell cancer in current clinical practise.Vascularity of primary and metastatic renal cell carcinoma specimens.Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model.The role of cytoreductive nephrectomy in the era of molecular targeted therapy.A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.Adjuvant and neoadjuvant therapy in renal cell carcinoma.Is there a role for presurgical therapy for renal cell carcinoma?Long-term management of patients with metastatic renal cell carcinoma on targeted agents.Clinical guidance on the perioperative use of targeted agents in solid tumor oncology.Surgical management of large renal tumors.Neoadjuvant and adjuvant treatment of renal cell carcinoma.Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside.Cytoreductive nephrectomy: past, present and future.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.Landmarks in the diagnosis and treatment of renal cell carcinoma.Role of targeted therapy in combination with surgery in renal cell carcinoma.Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.Is there a role for neoadjuvant targeted therapy to downsize primary tumors for organ sparing strategies in renal cell carcinoma?
P2860
Q26749084-C031CB0E-4F42-4C8B-B462-A6DAD829BFB7Q26774134-3A068F45-7770-4182-9169-1F81F7343FF2Q33588739-52640D5C-BCDB-49E0-869B-1CA06F64A30AQ33708158-83163E7C-F0A2-4F86-B6AA-0858D0900283Q33740717-F7475229-9650-44E2-96CC-193E87A46425Q34065685-E9733DCB-9F28-4D3C-A69F-216CD3702FF0Q34088696-C4F97102-2DD2-4151-AC93-27F771C7D127Q34572309-C3A7AF24-BB20-402F-8E65-2E4AE6C4D9D3Q34656393-0F3FF5A3-5C75-4A7A-93B8-7BA7DA260EF9Q34854084-E1EAEB90-4F5A-4B7A-96DC-5287C6174EE5Q34880943-FF99FE8B-A68F-4CC4-9EEC-3D05A304407EQ35018381-2C18B098-1211-47FD-925D-416F6F8D0EE7Q35115559-E2CC4EA8-9A69-40E4-819D-431B28D25EBFQ35210685-806B88E3-8923-4409-A89B-BA0312D6CA71Q35230406-7A1F52E8-876E-42B0-A361-7F06F1F83F25Q35413876-D3B674ED-DC8C-43F1-8088-9C38C9B47AB9Q35903850-FBE4CB62-DA49-4A94-9ADB-8583F69EA359Q36084067-A421E1A5-3899-4090-908A-89306FD79550Q36578610-B38FD836-C51F-4014-BE63-EC693A570C17Q36785907-EDB25E59-DE9C-46AA-88B2-38ADDC4F874BQ37165842-74D8CC6F-EA8A-4E4B-B90A-71324057B8C5Q37389557-6FF015F3-39DC-4406-9593-B1545911441CQ37404963-C65A02F9-2826-45B7-B293-EBE65E0EC664Q37492442-D41626A7-9F52-46A2-ABB4-56D06FE3EA7BQ37765582-475CFFA3-1DF6-4718-8346-6CDA4F8F29E4Q37812603-79A150F3-75B7-41FF-AA4B-006985F976B4Q37876494-315BDF65-ACC5-4AAE-BD9D-B734D0C95CE3Q37960913-78E7A694-8F94-415A-9A77-E687DB008433Q38020243-E32A3032-BCB5-49CC-9BAE-68CBD382D7D7Q38020245-683F1F0A-EC48-4B37-97F2-B7A700AD7217Q38068585-4D2FD7F4-011B-44DF-AAB0-542D7EA863FEQ38094592-BCB7A0F8-0E81-4C54-888F-063E0C8F4CFBQ38171327-1A419F5F-EC77-49E6-B1D9-F63C6EDFA8FBQ38176034-7C235644-3E67-47A8-A430-99FD3D5EB766Q38202061-CFCEBA54-C8B9-458F-BD99-3254417A21E7Q38238966-E781A45D-2024-4FFF-8596-1065E0A6331AQ38560110-FA16F3C1-3F3A-4626-A504-B0566F1D6E19Q40707153-CF632C52-19C5-4E3D-A49D-41F3EB7C1224Q41660750-C8E623F8-DD72-4F1A-9A9B-CB8BB5988C6BQ41886782-47CD339E-DC8F-46F3-BB40-7079D564B25B
P2860
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@en
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@nl
type
label
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@en
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@nl
prefLabel
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@en
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@nl
P2093
P1476
Sunitinib for treatment of advanced renal cell cancer: primary tumor response.
@en
P2093
Alfons J M van den Eertwegh
Astrid A M van der Veldt
Epie Boven
Gijsbert de Gast
John B A G Haanen
P304
P356
10.1158/1078-0432.CCR-07-4089
P407
P577
2008-04-01T00:00:00Z